These results provide evidence that SalC mitigates ischemic stroke in vivo by inhibiting the TLR4-TREM1-NF-κB pathway and blocking neuroinflammation, suggesting that SalC is a promising new drug for the treatment of early ischemic stroke. The gene discussed is TLR4; the disease is ischemic stroke.